Status:
UNKNOWN
The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Lead Sponsor:
Peking University
Conditions:
Peripheral T Cell Lymphoma
Eligibility:
All Genders
18-65 years
Brief Summary
The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 \& PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the cl...
Eligibility Criteria
Inclusion
- Patients with confirmed pathological diagnosis of aggressive PTCL
- Age 18-65 years old
- Achieving CR or PR after first-line therapy
Exclusion
- Subtypes with a more indolent course, including precursor T/natural killer neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, Sézary syndrome, and primary cutaneous CD30-positive disorders.
Key Trial Info
Start Date :
November 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04489264
Start Date
November 30 2020
End Date
November 30 2025
Last Update
December 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, China, 100142